Regulatory Affairs Outsourcing Market
The worldwide market for pharmaceuticals is projected to grow from around $1 trillion in 2015 to $1.3 trillion by 2020, representing an annual growth rate of 4.9 percent. Several global demographic and economic trends are driving pharmaceutical consumption, including a rapidly aging world population and an associated rise in chronic diseases, increased urbanization and higher disposable incomes, greater government expenditure on healthcare and growing demand for more effective treatments.
Meanwhile, market growth is shifting toward emerging markets in Asia, Latin America and elsewhere, where pharmaceutical sales are forecast to expand at double digit rates. Further reforms of legislative systems, especially regarding patent protection and enforcement, as well as improving regulatory conditions, will make these markets increasingly attractive for U.S. industry.
In the past few years rate of outsourcing of regulatory affairs activities has increased across life sciences industries. Recent findings by Transparency Market Research state that the global regulatory affairs outsourcing market will exhibit a healthy 11.5% CAGR from 2015 to 2023. As a result, the market, which had a valuation of US$1.9 Bn in 2014 will rise to US$5.7 bn by 2023.
Clinical Trial Application and Product Registration Services to be Key Enabler of Growth Over the next few years, however, the market for regulatory affairs outsourcing witnesses the highest gains from the clinical trial applications and product registration segment. Factors such as patent expiries and the rising prevalence of a number of chronic, viral, and bacterial diseases have prompted biopharmaceutical companies in the development of a large number of new products. With the rising number of products in clinical trials, the demand for clinical trial application and product registration services is expected to substantially rise in the next few years.
Emerging Economies like India to be Key Enabler of Growth
Economic and competitive pressures in the healthcare industry continue to motivate life sciences companies to find ways of cutting costs. Companies aspiring to widen their global reach are increasing investments on R&D activities and new products are entering clinical trials and the market at a rapid pace. Undertaking regulatory affairs and the maintenance of huge data generated during the process can be a complex task for companies having a range of product portfolio and operations spread across diverse regional markets.
In the years to come, regulatory affairs service providers in emerging economies across regions like India are expected to bag the most numbers of outsourcing projects across the globe due to their cost advantage. An increased number of biopharmaceutical companies are using emerging economies as a launch pad for their venture in larger markets such as North America and Europe.
As a result, the market for regulatory affairs outsourcing market in emerging economies will offer the most lucrative and sustained growth opportunities for the global market. The market is expected to expand at a 15.8% CAGR in Asia Pacific and 11.1% CAGR across Latin America from 2015 to 2023.